Clinical Trial Update: 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

This entry provides an update on a Phase 2 clinical trial comparing 18F-DCFPyL PSMA PET imaging with 18F-NaF PET for detecting metastatic prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 18F-DCFPyL (DCFPyL radiotracer for PSMA imaging)
• 18F-NaF (sodium fluoride labeled with fluorine-18)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Prostate Cancer, Prostatic Neoplasms | Phase 2 | Status: ACTIVE_NOT_RECRUITING